Clinical Report: Raman Tool Opens the Door to Continuous Vaccine Manufacturing
Overview
Researchers at Purdue University and Merck & Co. developed a Raman spectroscopy-based tool for real-time monitoring of viral particles during vaccine manufacturing. This innovation aims to streamline quality control processes, significantly reducing time and enhancing product yield and quality.
Background
The COVID-19 pandemic highlighted the urgent need for efficient vaccine manufacturing processes. Traditional methods involve time-consuming off-line quality control that can delay production and increase risk. Continuous monitoring technologies, such as Raman spectroscopy, offer a solution to enhance the speed and reliability of vaccine production.
Data Highlights
Remove placeholder text and consider including qualitative insights or implications from the source.Key Findings
- The Raman spectroscopy tool allows for real-time monitoring of viral particles without damaging them.
- Each test takes approximately 30 seconds, significantly reducing quality control time.
- The tool can be integrated into continuous manufacturing processes, facilitating early detection of defects.
- Initial experiments successfully captured Raman spectra specific to viral particles.
- Future research will explore portable Raman systems for in-line monitoring in commercial manufacturing.
Clinical Implications
The implementation of this Raman spectroscopy tool could revolutionize vaccine manufacturing by enabling rapid quality control and reducing production costs. Clinicians and manufacturers may benefit from improved product consistency and quality assurance.
Conclusion
Reiterate the significance of the tool in the context of ongoing global health challenges.
References
- The analytical scientist, Beating Biopharma Manufacturing Bottlenecks with Raman Spectroscopy, 2026 -- Beating Biopharma Manufacturing Bottlenecks with Raman Spectroscopy
- the medicine maker, The New Blueprint for Vaccine Development, 2026 -- The New Blueprint for Vaccine Development
- The analytical scientist, Raman Spectroscopy Moves to the Front Line of Pandemic Preparedness, 2026 -- Raman Spectroscopy Moves to the Front Line of Pandemic Preparedness
- the medicine maker, Scaling Smarter: How Continuous Manufacturing Is Reshaping Drug Development, 2026 -- Scaling Smarter: How Continuous Manufacturing Is Reshaping Drug Development
- Working document QAS/24.957, WHO, 2025 -- Points to consider in continuous manufacturing
- Annex 9, WHO -- Guidelines on clinical evaluation of vaccines
- Real-time monitoring of attenuated cytomegalovirus using Raman spectroscopy allows non-destructive characterization during flow - PubMed -- Real-time monitoring of attenuated cytomegalovirus using Raman spectroscopy
- Working document QAS/24.957
- Annex 9 Guidelines on clinical evaluation of vacci
- Real-time monitoring of attenuated cytomegalovirus using Raman spectroscopy allows non-destructive characterization during flow - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
About the Author(s)
James Strachan
Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at. From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.
